medigraphic.com

2012, Number 1

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2012; 50 (1)

Hepatic steatosis and type 2 diabetes mellitus in health workers

Salas-Flores R, González-Pérez B, Echegollen-Guzmán A

Language: Spanish
References: 30
Page: 13-18
PDF size: 35.80 Kb.


ABSTRACT

Background: patients with type 2 diabetes mellitus (T2DM) appear to have an increased risk of developing nonalcoholic fatty liver disease (NAFLD) and have higher risk to develop hepatic fibrosis and cirrhosis. The aim was to determine the prevalence of NAFLD in health workers with T2DM by liver ultrasound.
Methods: health workers with T2DM attended at the Family Medicine Unit No. 77, Madero City, Tamaulipas, Mexico, were screened. Risk factors, BMI, % of body fat (% BF), fat mass, waist circumference (WC), blood pressure, HbA1C and lipid profile, were evaluated. The patients were categorized into two groups according to NAFLD status. Differences between groups were assessed by independent t test and χ2 test.
Results: the NAFLD prevalence found in females on ultrasound examination was 40 % and 17.1 % in males. NAFLD patients were more obese (p ‹ 0.001) and they had significantly higher values of % BF (p ‹ 0.001), fat mass (p ‹ 0.01) and WC (p ‹ 0.01). They also had significantly higher values of HbA1C (p ‹ 0.04) and triglycerides (p ‹ 0.03) than patients without NAFLD.
Conclusions: NAFLD is common among health workers with T2DM. It is important to prevent NAFLD progression.


REFERENCES

  1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231.

  2. Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine R. Alanine aminotransferase as a marker of nonalcoholic fatty liver diasease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev 2006;22(6):437-443.

  3. Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Fiorello S, et al. Insulin resistance, the metabolic síndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2005;90(3):1578-1582. Disponible en http://jcem. endojournals.org/content/90/3/1578.long

  4. Targher G, Bertolini L, Padovani R, Zenari L, Zoppini G, Falezza G. Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men. Role of visceral fat accumulation. Diabetes Care 2004;27(10):2498-2500. Disponible en http://care.diabetesjournals.org/content/27/10/ 2498.long

  5. Shibata M, Kihara Y, Taguchi M, Tashiro M, Otsuki M. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care 2007;30(11):2940-2944. Disponible en http://care. diabetesjournals.org/content/30/11/2940.long

  6. Shakil A, Church RJ, Rao S. Gastrointestinal complications of diabetes. Am Fam Phys 2008;77(12):1697-1702.

  7. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006;40(Suppl 1):S17-S29.

  8. Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005;16(4):421-427.

  9. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50(8):1844- 1850. Disponible en http://diabetes.diabetesjournals.org/ content/50/8/1844.long

  10. Lluch I, Ascaso JF, Mora F, Minguez M, Peña A, Hernández A, et al. Gastroesophageal reflux in diabetes mellitus. Am J Gastroenterol 1999;9(4)4:919-924.

  11. Day CP. Non-alcoholic fatty liver disease: current concepts and management strategies. Clin Med 2006;6(1):19-25.

  12. Medina J, Fernández-Salazar LI, García-Buey L, Moreno- Otero R. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care 2004;27(8): 2057-2066. Disponible en http://care. diabetesjournals.org/ content/27/8/2057.long

  13. Ebert EC. Gastrointestinal complications of diabetes mellitus. Dis Mon 2005;51(12):620-663.

  14. Global database on body mass index [Base de datos en internet]. World Health Organization: Geneva. [Consultado el 24 de agosto de 2010.] Disponible en http://www. who.int/bmi/index.jsp

  15. Aguilar-Salinas CA, Gómez-Pérez FJ, Lerman-Garber I, Vázquez-Chávez C, Pérez-Méndez O, Posadas-Romero C. Diagnóstico y tratamiento de las dislipidemias: posición de la sociedad mexicana de endocrinología y nutrición. Rev Endocrinol Nutr 2004;12(1):1:7-41.

  16. Instituto Mexicano del Seguro Social. Guía de práctica clínica. Diagnóstico y tratamiento de la hipertensión arterial en el primer nivel de atención. México: Instituto Mexicano del Seguro Social; 2010. Disponible en http://www.imss.gob. mx/SiteCollectionDocuments/migracion/profesionales/ GuiasClinicas/GER_HIPERTENSION_1ERN.pdf

  17. American Diabetes Association. Standards of medical care. Diabetes Care 2010;33(Suppl 1):s11-s61.

  18. Instituto Mexicano del Seguro Social. Guía de práctica clínica. Diagnóstico y tratamiento de la diabetes mellitus tipo 2 en el primer nivel de atención. México: Instituto Mexicano del Seguro Social; 2009. Disponible en http://www.imss.gob. mx/SiteCollectionDocuments/migracion/profesionales/ GuiasClinicas/GERDiabetesMellitusTipo2.pdf

  19. Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Red Ed) 1986;292(6512):13-15. Disponible en http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1338970/ ?tool=pubmed

  20. Petit JM, Guiu B, Terriat B, Loffroy R, Robin I, Petit V, et al. Nonalcoholic fatty liver is not associated with carotid intima- media thickness in type 2 diabetic patients. J Clin Endocrinol Metab 2009;94(10):4103-4106.

  21. Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007; 30(3):734-743.

  22. Bernal-Reyes R, Sáenz-Labra A, Bernardo-Escudero R. Prevalencia de la esteatohepatitis no alcohólica (EHNA). Rev Gastroenterol Mex 2000;65(2):58-62.

  23. Roesch-Dietlen F, Dorantes-Cuéllar A, Carrillo-Toledo MG, Martínez-Sibaja C, Rojas-Carrera S, Bonilla-Rojas S, et al. Frecuencia del hígado graso no alcohólico en un grupo de pacientes con síndrome metabólico estudiado en la Ciudad de Veracruz. Rev Gastroenterol Mex 2006;71(4):446-452.

  24. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000;132(2):112-117.

  25. Kral JG, Schaffner F, Pierson RN, Wang J. Body fat topography as an independent predictor of fatty liver. Metabolism 1993;42(5):548-551.

  26. Kotronen A, Juurinen L, Hakkarainen A, Westerbacka J, Corner A, Bergholm R et al. Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care 2008;31(1):165-169. Disponible en http://care.diabetesjournals.org/content/31/1/ 165.long

  27. Church TS, Kuk JL, Ross R, Priest EL, Biltoft E, Blair SN. Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease. Gastroenterology 2006;130(7):2023-2030.

  28. Sharabi Y, Eldad A. Nonalcoholic fatty liver disease is associated with hyperlipidemia and obesity. Am J Med 2000; 109(2):171-175.

  29. Stefan N, Kantartzis K, Häring HU. Causes and metabolic consequences of fatty liver. Endocr Rev 2008;29(7):939-960.

  30. Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007; 30(3):734-743. Disponible en http://care.diabetesjournals. org/content/30/3/734.long




2020     |     www.medigraphic.com